TRUCKs: the fourth generation of CARs

@article{Chmielewski2015TRUCKsTF,
  title={TRUCKs: the fourth generation of CARs},
  author={M. Chmielewski and H. Abken},
  journal={Expert Opinion on Biological Therapy},
  year={2015},
  volume={15},
  pages={1145 - 1154}
}
Introduction: Adoptive cell therapy of malignant diseases takes advantage of the cellular immune system to recognize and destroy cancer cells. This is impressively demonstrated by redirecting T cells with a chimeric antigen receptor (CAR) towards CD19, inducing complete and lasting remission of leukemia in more than two-thirds of patients in early phase trials. Areas covered: We outline how the CAR strategy is highly specific in redirecting T cells towards pre-defined target cells, however… Expand

Paper Mentions

Interventional Clinical Trial
According to the high expression of tumor cell-associated antigen CD138, integrin β7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation… Expand
ConditionsRRMM
InterventionBiological
CARs on the Highway: Chimeric Antigen Receptor Modified T Cells for the Adoptive Cell Therapy of Malignant Diseases
TLDR
The chapter reviews the differences in CAR design, the success in the treatment of hematologic malignancies, the challenges in treating solid cancer, the treatment-related toxicities, and strategies to improve safety of CAR T cell therapy. Expand
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
TLDR
The generations in CAR design, the impact of specific modifications, the strategies to improve the safety of CAR T cell therapy, and the challenges to adapt the CAR design for broader applications are reviewed. Expand
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
TLDR
A CAR-CD19 T cell that secretes a CD19-anti-Her2 bridging protein that can be exploited to attack tumor antigens on any cancer, and incorporates critical attributes for successful solid tumor cell therapy. Expand
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
TLDR
A CAR-CD19 T cell that secretes a CD19-anti-Her2 bridging protein that can be exploited to attack tumor antigens on any cancer, and incorporates critical attributes for successful solid tumor cell therapy. Expand
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
TLDR
The goal of this review is to summarize some of the most recent aspects ofCAR-T cell design and manufacturing that have led to successes in hematological malignancies, allowing the reader to appreciate the barriers that must be overcome to extend CAR-T therapies to solid tumors successfully. Expand
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
TLDR
This review sums up the current stage of knowledge about target-selection, adverse events like on/off-tumor toxicity, the preclinical and clinical studies of CAR-T therapy, and the characteristics of strategies applied in CRC. Expand
A long way to the battlefront: CAR T cell therapy against solid cancers
TLDR
The advantages and some of the key hurdles encountered by CAR T cell therapy in solid tumors as well as the strategies adopted to improve therapeutic outcomes of this approach are discussed. Expand
Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors
TLDR
Two of the problems that are currently perceived as limiting the success of the clinical translation of CAR-T cells in solid tumors are explored: namely, the recruitment and survival of tumor-specific T cells in the microenvironment. Expand
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
TLDR
This review focuses on the editing of immune cells to introduce such novel receptors to improve immune responses to cancer, with two promising candidates known as chimeric-antigen receptors (CARs), or T-cell receptors (TCRs) with high tumour specificity. Expand
Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
TLDR
A novel CAR-T platform that has the ability to increase the persistence ofCAR-T cells in solid tumors through exogenous expression of persistent genes is demonstrated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
TLDR
It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL). Expand
CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
TLDR
A newly described strategy for overcoming some of the shortcomings of adoptive T cell therapy by engineering CAR T cells with inducible or constitutive release of IL-12 is reviewed. Expand
Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells
TLDR
Two broadly applicable approaches are developed to improve tumor targeting based on combinatorial antigen recognition and receptors that provide antigen-specific inhibition, which are named iCARs to divert T cells from the normal tissues one wants to protect. Expand
Exploiting the curative potential of adoptive T‐cell therapy for cancer
TLDR
Recent clinical trials of TILs and antigen receptor gene therapy for advanced cancers are reviewed and lessons from this experience are discussed and considered how they might be applied to realize the full curative potential of ACT. Expand
Chimeric antigen receptors for T-cell based therapy.
TLDR
This chapter focuses upon methods to modify T-cells from both species to generate CAR T- cells for functional testing as a generic tool broadening the potential of applicability of adoptive T-cell therapy. Expand
The T-body approach: redirecting T cells with antibody specificity.
  • Z. Eshhar
  • Biology, Medicine
  • Handbook of experimental pharmacology
  • 2008
TLDR
The T-bodies are advantageous because their tumor recognition is not HLA-specific and, therefore, the same constructs can be used for a wide spectrum of patients and cancers. Expand
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
TLDR
The results show how IL-12 supplementation by CAR T cells can target otherwise inaccessible tumor lesions, in a manner associated with reduced systemic toxicity, by recruiting and activating innate immune cells for a proinflammatory response. Expand
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
TLDR
Preclinical studies are presented demonstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)-modified T cells that are further modified to constitutively secrete IL-12 are able to safely eradicate established disease in the absence of prior conditioning. Expand
CD19-CAR Trials
TLDR
Given their remarkable activity, CD19-CAR T cells are likely to be quickly incorporated into the management of B-cell neoplasms; these cells have become the paradigm for similar strategies targeting other cancers. Expand
Building better chimeric antigen receptors for adoptive T cell therapy.
TLDR
A structural overview of CAR development is provided and possible reasons for conflicting results are identified in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs. Expand
...
1
2
3
4
5
...